(Q35607581)

9 August 2017

title

Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India (English)

1 reference

9 August 2017

main subject

phase IV clinical trial

0 references

India

0 references

visceral leishmaniasis

1 reference

1 reference

Supriyo Mukherjee

5

0 references

Shyam Sundar

7

object named as

Shyam Sundar

1 reference

9 August 2017

Prabhat K Sinha

1

1 reference

9 August 2017

T K Jha

2

1 reference

9 August 2017

Chandreshwar P Thakur

3

1 reference

9 August 2017

Devendra Nath

4

1 reference

9 August 2017

Amrendra Kumar Aditya

6

1 reference

9 August 2017

publication date

17 November 2011

1 reference

Journal of Tropical Medicine

9 August 2017

published in

1 reference

9 August 2017

volume

2011

1 reference

9 August 2017

page(s)

645203

1 reference

Creative Commons Attribution 3.0 Unported

9 August 2017

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

Creative Commons Attribution 3.0 Unported

0 references

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Elimination of neglected tropical diseases in the South-East Asia Region of the World Health Organization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Injectable paromomycin for Visceral leishmaniasis in India

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Oral miltefosine for Indian visceral leishmaniasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

A teratological study of aminoglycoside antibiotic treatment during pregnancy.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235903

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

25 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2011%2F645203

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22174722

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2011/645203

1 reference

9 August 2017

1 reference

9 August 2017

1 reference